Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13803708 | 0.87 | HPGD (0.74) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL6648776 | 0.84 | NPC1 (0.76) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL3532448 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL12047247 | 0.83 | KDM4E (0.72) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL3533289 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL9482692 | 0.80 | SMN1; SMN2 (0.66) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL29790286 | 0.80 | NPC1 (0.69) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| Procodazole SCHEMBL838841 | 0.80 | CHRM1 (1.00) | KDM4EALDH1A1NPC1RAB9AHTT | |
| SCHEMBL30868868 | 0.80 | KDM4E (0.76) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| Procodazole SCHEMBL29404024 | 0.80 | CHRM1 (1.00) | KDM4EALDH1A1NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4181724-A | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | claimed |
| WO-2017194958-A1 | ASSAY | SCHOFIELD CHRISTOPHER J (GB) | 2017-11-16 | — | — | WO | disclosed |
| EP-2737079-B1 | ASSAY FOR HISTIDINYL HYDROXYLASE ACTIVITY | UNIV OXFORD INNOVATION LTD (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-2675912-B1 | METHOD FOR ASSAYING OGFOD1 ACTIVITY | OXFORD UNIVERSITY INNOVATION LTD (GB) | 2016-11-16 | — | — | EP | disclosed |
| US-9422589-B2 | Assay for histidinyl hydroxylase activity | ISIS INNOVATION LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9228224-B2 | Method for assaying OGFOD1 activity | ISIS INNOVATION LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-20140248636-A1 | ASSAY FOR HISTIDINYL HYDROXYLASE ACTIVITY | ISIS INNOVATION LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| EP-2737079-A1 | ASSAY FOR HISTIDINYL HYDROXYLASE ACTIVITY | ISIS Innovation Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20140051106-A1 | METHOD FOR ASSAYING OGFOD1 ACTIVITY | ISIS INNOVATION LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140045930-A1 | ASSAY FOR ARGINYL HYDROXYLASE ACTIVITY | ISIS INNOVATION LIMITED (GB) | 2014-02-13 | — | — | US | disclosed |
| EP-0901468-B1 | PREPARATION OF LACTAMS FROM ALIPHATIC ALPHA,OMEGA-DINITRILES | DU PONT (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6077955-A | CONTACTING AN AQUEOUS PRODUCT MIXTURE CONTAINING A W-NITRILOCARBOXYLIC ACID AMMONIUM SALT WITH HYDROGEN AND A HYDROGENATION CATALYST, WHEREBY THE SALT IS CONVERTED DIRECTLY TO THE CORRESPONDING LACTAM WITHOUT ISOLATION OF INTERMEDIATES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| US-6066490-A | MICROORGANISMS THAT PRODUCES A HYDROLASE ENZYME THAT DEMONSTRATES PREFERENTIAL ACTIVITY | E. I. DU PONT DE NEMOURS & COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5936114-A | Preparation of lactams from aliphatic α, ω-dinitriles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-08-10 | — | — | US | disclosed |
| US-5922589-A | ISOLATED COMAMONAS TESTOSTERONI 5-MGAM-4D WITH NITRILE HYDRATASE AND AMIDASE ACTIVITIES; FOR HIGH YIELD WITH HIGH REGIOSELECTIVITY AND BY PRODUCT INHIBITION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| US-5908954-A | CHEMICAL INTERMEDIATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0901468-A1 | PREPARATION OF LACTAMS FROM ALIPHATIC $g(a),$g(v)-DINITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5858736-A | CONTACTING DINITRILE IN AQUEOUS MIXTURE WITH ENZYME CATALYST HAVING ALIPHATIC NITRILASE ACTIVITY OR COMBINATION OF NITRILE HYDRATASE AND AMIDASE ACTIVITY, CONTACTING PRODUCT WITH HYDROGEN AND HYDROGENATION CATALYST TO PRODUCE LACTAM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-01-12 | — | — | US | disclosed |
| US-5814508-A | TREATING A WHOLE CELL CATALYST TO SELECT FOR A REGIOSELECTIVE NITRILASE ACTIVITY OR A NITRILE HYDRATASE ACTIVITY; CATALYTIC CONVERSION OF ALPHA-OMEGA DINITRILES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| WO-1997044318-A1 | PREPARATION OF LACTAMS FROM ALIPHATIC α,φ-DINITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045930-A1 | ASSAY FOR ARGINYL HYDROXYLASE ACTIVITY | PADI6, PADI3, PADI1 | KDM4E 559/4885ALDH1A1 770/4885HSD17B10 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.